Engineering a bioreactor that could withstand the hot and bumpy journey to space AND operate in zero gravity required some out-of-the-box thinking.
Our Chief Science Officer combined her knowledge across 5 degrees with principles of astrophysics and quantum biology to build a tool so that we could better understand protein folding and how biologicals behave in space.
After using this tool to create a novel method for harvesting native human proteins (ProgeniQ Proteins), we knew we were re-defining not just HOW but WHY specific biological interactions happen in the body.
This tool now forms the core of our proprietary in silico pharmacology program.
Our vision is TRUE personalised medicine
Our mission is to develop a world-leading tool that can predict the clinical effects of pharmaceuticals - at the patient level.
Discover OmnigeniQ's method for harvesting native proteins as an alternative to recombinant technology
The ICC’s Venture Catalyst Space acceleration program is designed for startups developing new services or products for the space industry.
In this video, OmnigeniQ Co-Founder and Chief Science Officer, Tiffanwy Klippel-Cooper, talks about our earliest project for the space industry.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.